Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment.
Alzheimer's disease (AD) brain is marked by severe neuronal death which has been partly attributed to increased oxidative stress. The pathophysiology accounting for this free radical injury is not well-delineated at this point, but one hypothesis is that a derangement in transition metal metabolism contributes to the process. We tested the hypothesis that peripheral derangement of transition metal metabolism is present early in the dementing process. We analyzed non-heme iron and copper levels in serum from subjects with normal cognition, mild cognitive impairment, and early stage senile dementia and followed these subjects over 5 years. An increase in the ratio of serum copper to non-heme iron levels predicted which subjects with mild cognitive impairment would progress to dementia versus those that would remain cognitively stable. This increase did not correlate with changes in expression of iron regulatory protein 2 or selected downstream targets in peripheral lymphocytes. A cDNA-based microarray (IronChip) containing genes relevant to iron and copper metabolism was used to assess transition metal metabolism in circulating lymphocytes from cognitively normal and demented subjects. No gene was identified as being dysregulated more than 2-fold, and verification using quantitative RT-PCR demonstrated no significant changes in expression for ALAS2, FOS, and CTR1. The increased ratio of serum copper to serum iron prior to dementia has potential as a biomarker for cognitive decline and mirrors other changes in serum previously reported by others, but iron and copper metabolism pathways appear to be broadly unaffected in peripheral blood in AD.
Neurosurgery Center for Research, Loma Linda University, Loma Linda, CA, USA.
Claudius
C
Mueller
Matthew
M
Schrag
Andrew
A
Crofton
Jens
J
Stolte
Martina U
MU
Muckenthaler
Shino
S
Magaki
Wolff
W
Kirsch
D000368:Aged; D000369:Aged, 80 and over; D027682:Cation Transport Proteins / Q000235:genetics / Q000378:metabolism; D060825:Cognitive Dysfunction / Q000097:blood* / Q000503:physiopathology*; D003300:Copper / Q000097:blood*; D005260:Female; D020869:Gene Expression Profiling; D006706:Homeostasis; D006801:Humans; D007501:Iron / Q000097:blood*; D035942:Iron Regulatory Protein 2 / Q000235:genetics / Q000378:metabolism; D008137:Longitudinal Studies; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D009483:Neuropsychological Tests; D020411:Oligonucleotide Array Sequence Analysis; D000099236:Solute Carrier Family 11, Member 2
D027682:Cation Transport Proteins; D003300:Copper; D007501:Iron; D035942:Iron Regulatory Protein 2; D000099236:Solute Carrier Family 11, Member 2